Skip to content

FUJIY changes

Pick any two versions below to diff them.

View the full Nov 14, 2026 version
Price
$11.50
Discount category
Close to intrinsic value
Intrinsic value source
AI estimate
Next earnings
Feb 9, 2027
Next earnings is estimate
Yes
Company name
added: Fujifilm Holdings
Sector
added: Healthcare, semiconductor materials, office equipment and imaging
About
added: FUJIFILM Holdings Corporation (FUJIY) is a Japanese company with four segments. Healthcare makes medical imaging systems, endoscopes and medical IT, and it makes biologic drugs under contract for drug companies (Bio CDMO). Electronics makes semiconductor materials, such as CMP slurries and photoresists, and data tapes. Business Innovation sells office printers and multifunction devices, IT services and printing equipment. Imaging sells instax instant cameras and film, and digital cameras. In the six months to September 30, 2026, revenue was ¥1,711.5 billion: ¥554.1 billion from Healthcare, ¥259.6 billion from Electronics, ¥566.7 billion from Business Innovation and ¥331.1 billion from Imaging. Revenue was ¥3,357.0 billion in the fiscal year to March 31, 2026. The head office is in Tokyo, and Teiichi Goto is president and chief executive officer. The ADRs trade over the counter in US dollars, and one ADR is one-half of one ordinary share. Fujifilm reports in yen under US GAAP, and its fiscal year ends on March 31.
Thesis
added: The market prices Fujifilm below the AI estimate because profit fell while the company spends heavily on new plants. In the six months to September 30, 2026, revenue grew 8.8%, but operating income fell 10.9%. The Healthcare segment earned only ¥3.4 billion, because the new Bio CDMO plants add fixed costs and some smaller plants stopped for a time after regulatory inspections. Business Innovation had a small loss after one-time costs. Free cash flow was negative ¥36.6 billion in the half year, and short-term debt rose. For the value to rise, three things must be true. The Bio CDMO plants in Denmark and North Carolina must fill with orders and lift the Healthcare margin. Semiconductor materials must keep growing with AI chip demand, as in the half year, when operating income of the Electronics segment rose 51.3%. And Fujifilm must reach its forecast of ¥365.0 billion of operating income for the fiscal year to March 2027, which needs a much stronger second half. The results for the nine months to December 31, 2026, expected in February 2027, are the next test. A decision on the partial spin-off of Business Innovation can come later.
Valuation
added: The intrinsic value for Fujifilm Holdings is an AI estimate from November 14, 2026. It is not an analyst's value. An AI research agent calculated it from the reports of Fujifilm in yen, because Fujifilm does not file periodic reports with the SEC. The estimate is in US dollars per ADR. The method is a multiple of net income per share for the fiscal year that ends on March 31, 2028. The financial results for the fiscal year that ended on March 31, 2026 (May 12, 2026) give revenue of ¥3,357.0 billion, operating income of ¥350.2 billion and net income of ¥276.7 billion, or ¥229.65 per share. The financial results for the six months that ended on September 30, 2026 (November 9, 2026) give revenue of ¥1,711.5 billion, operating income of ¥141.2 billion and net income of ¥105.2 billion for the half year. They keep the forecast for the fiscal year that ends on March 31, 2027 at operating income of ¥365.0 billion and net income of ¥280.0 billion, or ¥234.10 per share. They give 1,234,150,284 shares issued and 38,066,444 treasury shares at September 30, 2026, so the estimate uses 1,196,083,840 shares. They give short-term debt of ¥383.4 billion, long-term debt of ¥598.6 billion and cash of ¥145.9 billion. The multiple applies to net income after interest, so the estimate does not subtract the debt again. The deposit agreement that Citibank filed with the SEC (Form F-6 POS, April 1, 2024) states that each ADS represents one-half of one share, and the forms of Deutsche Bank, The Bank of New York Mellon and JPMorgan give the same ratio. The estimate assumes 160.00 yen per US dollar, from the ECB reference rates of November 13, 2026. The net income per share for the fiscal year to March 2028 and the multiples are assumptions. The low case assumes ¥220, because the fixed costs of the new Bio CDMO plants stay high and office equipment sales fall, at 13 times. It gives $8.94 per ADR. The base case assumes ¥255, with higher use of the Bio CDMO plants and growth in semiconductor materials, at 16 times. It gives $12.75 per ADR. The high case assumes ¥290, with full use of the Bio CDMO plants and strong AI chip demand, at 19 times. It gives $17.22 per ADR. The estimate assumes weights of 25%, 50% and 25%. The weighted intrinsic value is $12.91 per ADR. The estimate leaves out the possible partial spin-off of the Business Innovation business, because its terms are not decided. Intangible assets and switching costs apply. Fujifilm says that its copper interconnect CMP slurry and NTI developers have the top global market share, chip makers must qualify each material for each process, and instax sales continue to grow. But office equipment is a mature market, and the Bio CDMO business competes with large contract makers, so the estimate expects an advantage that lasts 10 years or more, but not 20 years. As of Nov 14, 2026.
Risks
added: Fujifilm spends heavily on large Bio CDMO plants, and their fixed costs cut Healthcare operating income by 85.8% in the six months to September 30, 2026. Some smaller plants stopped production for a time after regulatory inspections, and operations started again at the end of September 2026. If orders do not fill the plants, the return on this investment stays low. Business Innovation revenue fell 1.0% in the six months to September 30, 2026, with lower exports to Europe and the United States and lower sales in China. The partial spin-off of this business is only under assessment, and its terms and timing are not decided. Rising raw material costs reduced operating income in the six months to September 30, 2026. In May 2026, Fujifilm estimated that crude oil at US$100 per barrel, after the tensions in the Middle East, can cut operating income by ¥3.0 billion to ¥4.0 billion a quarter. Overseas sales were 68.8% of revenue in the six months to September 30, 2026. A stronger yen lowers the results in yen. The ADRs trade over the counter, and Fujifilm does not file reports with the SEC. A US holder gets the yen dividend after currency conversion, depositary fees and Japanese withholding tax.
Balance sheet
added: Cash: ¥145.9B Debt: ¥981.9B Net debt: ¥836.1B Debt due within 12 months: ¥383.4B At September 30, 2026, Fujifilm had cash and cash equivalents of ¥145.9 billion. Short-term debt was ¥383.4 billion and long-term debt was ¥598.6 billion, a total of ¥981.9 billion. In the six months to September 30, 2026, Fujifilm borrowed ¥100.0 billion of long-term debt, and net cash from operating activities of ¥195.1 billion did not cover investment of ¥231.7 billion, mainly in new plants. Shareholders' equity was ¥3,815.8 billion, or 62.5% of total assets, and the current ratio was 125.4%. Operating lease liabilities of ¥136.3 billion are not in debt. As of Sep 30, 2026.
Checkpoints
added: Feb 9, 2027 (estimate): Results for the nine months to December 2026. Pending. Watch: Operating income for the nine months keeps Fujifilm on track for its forecast of ¥365.0 billion for the year, and the Healthcare margin recovers, and this passes; a lower forecast fails. May 2027 (estimate): Results for the fiscal year to March 2027 and the new forecast. Pending. Watch: Net income is near ¥280.0 billion and the forecast for the next fiscal year shows higher profit from Bio CDMO and semiconductor materials, and this passes; lower profit fails. 2027 (estimate): Decision on the partial spin-off of Business Innovation. Pending. Watch: Fujifilm announces the terms of the partial spin-off and the listing on the Tokyo Stock Exchange, and this passes; a stop of the assessment with no other plan fails.
Recent events
added: Nov 9, 2026: Fujifilm reported results for the six months to September 30, 2026. Revenue grew 8.8% to ¥1,711.5 billion, but operating income fell 10.9% to ¥141.2 billion and net income fell 12.5% to ¥105.2 billion. Operating income rose 51.3% in Electronics and 16.2% in Imaging. Healthcare earned only ¥3.4 billion because of higher fixed costs in Bio CDMO, and Business Innovation had a loss of ¥0.6 billion. Fujifilm raised its revenue forecast for the fiscal year to March 2027 to ¥3,590.0 billion and kept operating income at ¥365.0 billion and net income at ¥280.0 billion. Sep 9, 2026: Fujifilm agreed to transfer its printing plate plant in China and its printing plate sales outside Japan, the United States, Canada and Mexico to Huangshan Jinruitai Technology. The business had less than 1% of consolidated revenue. Aug 6, 2026: Fujifilm started to assess a partial spin-off of the Business Innovation business. It would keep less than 20% of FUJIFILM Business Innovation Corp., give the other shares to its shareholders as a dividend in kind and list the company on the Tokyo Stock Exchange. The segment had revenue of ¥1,174.8 billion in the fiscal year to March 2026. Fujifilm also reported first quarter results, with operating income down 32.0% to ¥51.2 billion. May 12, 2026: Fujifilm reported results for the fiscal year to March 31, 2026. Revenue grew 5.0% to ¥3,357.0 billion, operating income was ¥350.2 billion and net income was ¥276.7 billion. The dividend was ¥70.0 per share, and Fujifilm plans ¥75.0 per share for the next fiscal year. May 7, 2026: Fujifilm completed a share repurchase of 9,726,900 shares for ¥30.0 billion in April 2026, and it cancelled the shares on June 30, 2026.